Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints

Vikelis, Michail; Rikos, Dimitrios; Argyriou, Andreas A.; Papachristou, Pinelopi; Rallis, Dimitrios; Karapanayiotides, Theodoros; Galanopoulos, Andreas; Spingos, Konstantinos; Dimisianos, Nikolaos; Giakoumakis, Emmanouil; Zavridis, Periklis; Notas, Konstantinos; Vlachos, George S.; Soldatos, Panagiotis; Bilias, Konstantinos; Xiromerisiou, Georgia; Rudolf, Jobst; Dermitzakis, Emmanouil V.; Rapoport, Alan M.

doi:10.1080/14737175.2024.2365312

Expert Review of Neurotherapeutics

2024

DOI: 10.1080/14737175.2024.2365312

|View full text |Cite

Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints

Michail Vikelis,

Dimitrios Rikos,

Andreas A. Argyriou

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence

Edvinsson

2024

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence

Edvinsson

2024

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study

Dermitzakis,

Rikos,

Vikelis

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

Objectives: The present open-label multicenter pilot study sought to prospectively evaluate the efficacy and safety of rimegepant in treating migraine attacks. Methods: The primary endpoint was pain freedom at two hours post-dose, while the co-primary efficacy endpoints included a reduction in the headache intensity and freedom from the most bothersome symptoms (MBS) associated with migraine at the same time point. To test the potential efficacy of rimegepant, patients were asked to record in a questionnaire all the relevant changes with each migraine attack treated with rimegepant at two hours post-dose vs. two hours before. The attending neurologists provided information on the basic demographics, medical anamnesis, and migraine history as well as the triptan use history. Results: A total of 54 patients (32 with episodic and 22 with chronic migraine) received rimegepant 75 mg at least once during a single migraine attack (overall, 140 dosage intakes). Pain freedom at 2 h was achieved in 45/140 (32.1%) intakes. Regarding the efficacy of the first rimegepant dose (n = 54), significant reductions in the headache intensity were observed between the pre- and 2 h post-treatment average VAS scores (−4.8 ± 2.8 mean; p < 0.001). Likewise, the same mean reductions in the average VAS scores occurred when the 2 h response to all 140 doses was analyzed (−5 ± 2.8; p < 0.001). Freedom from MBS at 2 h post-dose was achieved for photophobia in 43%, for phonophobia in 53%, and for nausea in 57%. The ability to fully return to everyday activities at 2 h post-dose was achieved in 83/140 instances (59%). We only recorded mild adverse events in 24/140 dosages. Conclusions: Our preliminary results demonstrate that rimegepant is effective, safe, and well tolerated in treating acute migraine attacks.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints

Cited by 2 publications

References 35 publications

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence

Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence

Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study

Contact Info

Product

Resources

About